<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34820848</PMID><DateCompleted><Year>2022</Year><Month>04</Month><Day>01</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1398-9995</ISSN><JournalIssue CitedMedium="Internet"><Volume>77</Volume><Issue>4</Issue><PubDate><Year>2022</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Allergy</Title><ISOAbbreviation>Allergy</ISOAbbreviation></Journal><ArticleTitle>Mast cell activation is associated with post-acute COVID-19 syndrome.</ArticleTitle><Pagination><StartPage>1288</StartPage><EndPage>1291</EndPage><MedlinePgn>1288-1291</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/all.15188</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wechsler</LastName><ForeName>Joshua B</ForeName><Initials>JB</Initials><AffiliationInfo><Affiliation>Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Butuci</LastName><ForeName>Melina</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Allakos, Inc., Redwood City, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wong</LastName><ForeName>Alan</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Allakos, Inc., Redwood City, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kamboj</LastName><ForeName>Amol P</ForeName><Initials>AP</Initials><Identifier Source="ORCID">0000-0003-3611-7326</Identifier><AffiliationInfo><Affiliation>Allakos, Inc., Redwood City, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Youngblood</LastName><ForeName>Bradford A</ForeName><Initials>BA</Initials><AffiliationInfo><Affiliation>Allakos, Inc., Redwood City, California, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>Allakos, Inc</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>12</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>Allergy</MedlineTA><NlmUniqueID>7804028</NlmUniqueID><ISSNLinking>0105-4538</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007113" MajorTopicYN="N">Immunity, Innate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008407" MajorTopicYN="N">Mast Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID</Keyword><Keyword MajorTopicYN="N">inflammation</Keyword><Keyword MajorTopicYN="N">innate immunity</Keyword><Keyword MajorTopicYN="N">long covid</Keyword><Keyword MajorTopicYN="N">mast cells</Keyword></KeywordList><CoiStatement>J.B.W. provides medical advisory consulting for Allakos, Inc. regarding the use of lirentelimab with eosinophilic gastrointestinal diseases. J.B.W. is not employed by Allakos, Inc. and does not hold stock or stock options, and did not receive consulting fees from Allakos, Inc. for this manuscript; M.B., A.W., A.P.K., and B.A.Y. are employees of and hold stock or stock options in Allakos, Inc.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>10</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>8</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>11</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>11</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>11</Month><Day>25</Day><Hour>6</Hour><Minute>51</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>7</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34820848</ArticleId><ArticleId IdType="pmc">PMC9299596</ArticleId><ArticleId IdType="doi">10.1111/all.15188</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Demonbreun AR, McDade TW, Pesce L, et al. Patterns and persistence of SARS&#x2010;CoV&#x2010;2 IgG antibodies in Chicago to monitor COVID&#x2010;19 exposure. JCI Insight. 2021;6(9). 10.1172/jci.insight.146148</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.146148</ArticleId><ArticleId IdType="pmc">PMC8262291</ArticleId><ArticleId IdType="pubmed">33755598</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudre CH, Murray B, Varsavsky T, et al. Attributes and predictors of long COVID. Nat Med. 2021;27(4):626&#x2010;631. 10.1038/s41591-021-01292-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01292-y</ArticleId><ArticleId IdType="pmc">PMC7611399</ArticleId><ArticleId IdType="pubmed">33692530</ArticleId></ArticleIdList></Reference><Reference><Citation>Doykov I, Hallqvist J, Gilmour KC, Grandjean L, Mills K, Heywood WE. &#x2018;The long tail of Covid&#x2010;19&#x2019; &#x2010; The detection of a prolonged inflammatory response after a SARS&#x2010;CoV&#x2010;2 infection in asymptomatic and mildly affected patients. F1000Research. 2020;9:1349. 10.12688/f1000research.27287.2</Citation><ArticleIdList><ArticleId IdType="doi">10.12688/f1000research.27287.2</ArticleId><ArticleId IdType="pmc">PMC7745182</ArticleId><ArticleId IdType="pubmed">33391730</ArticleId></ArticleIdList></Reference><Reference><Citation>Patterson BK, Guevara&#x2010;Coto J, Yogendra R, et al. Immune&#x2010;based prediction of COVID&#x2010;19 severity and chronicity decoded using machine learning. Front Immunol. 2021;12:700782. 10.3389/fimmu.2021.700782</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.700782</ArticleId><ArticleId IdType="pmc">PMC8273732</ArticleId><ArticleId IdType="pubmed">34262570</ArticleId></ArticleIdList></Reference><Reference><Citation>Holmes E, Wist J, Masuda R, et al. Incomplete systemic recovery and metabolic phenoreversion in post&#x2010;acute&#x2010;phase nonhospitalized COVID&#x2010;19 patients: implications for assessment of post&#x2010;acute COVID&#x2010;19 syndrome. J Proteome Res. 2021;20(6):3315&#x2010;3329. 10.1021/acs.jproteome.1c00224</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jproteome.1c00224</ArticleId><ArticleId IdType="pubmed">34009992</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallukat G, Hohberger B, Wenzel K, et al. Functional autoantibodies against G&#x2010;protein coupled receptors in patients with persistent Long&#x2010;COVID&#x2010;19 symptoms. J Transl Autoimmun. 2021;4:100100. 10.1016/j.jtauto.2021.100100</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtauto.2021.100100</ArticleId><ArticleId IdType="pmc">PMC8049853</ArticleId><ArticleId IdType="pubmed">33880442</ArticleId></ArticleIdList></Reference><Reference><Citation>Gebremeskel S, Schanin J, Coyle KM, et al. Mast cell and eosinophil activation are associated with COVID&#x2010;19 and TLR&#x2010;mediated viral inflammation: implications for an anti&#x2010;Siglec&#x2010;8 antibody. Front Immunol. 2021;12:650331. 10.3389/fimmu.2021.650331</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.650331</ArticleId><ArticleId IdType="pmc">PMC7988091</ArticleId><ArticleId IdType="pubmed">33777047</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang L, Xie X, Tu Z, Fu J, Xu D, Zhou Y. The signal pathways and treatment of cytokine storm in COVID&#x2010;19. Signal Transduct Target Ther. 2021;6(1):255. 10.1038/s41392-021-00679-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-021-00679-0</ArticleId><ArticleId IdType="pmc">PMC8261820</ArticleId><ArticleId IdType="pubmed">34234112</ArticleId></ArticleIdList></Reference><Reference><Citation>Desai A, Jung MY, Olivera A, et al. IL&#x2010;6 promotes an increase in human mast cell numbers and reactivity through suppression of suppressor of cytokine signaling 3. J Allergy Clin Immunol. 2016;137(6):1863&#x2013;1871 e6. 10.1016/j.jaci.2015.09.059</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2015.09.059</ArticleId><ArticleId IdType="pmc">PMC4899186</ArticleId><ArticleId IdType="pubmed">26774658</ArticleId></ArticleIdList></Reference><Reference><Citation>Aigner L, Pietrantonio F, Bessa de Sousa DM, et al. The leukotriene receptor antagonist montelukast as a potential COVID&#x2010;19 therapeutic. Front Mol Biosci. 2020;7:610132. 10.3389/fmolb.2020.610132</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmolb.2020.610132</ArticleId><ArticleId IdType="pmc">PMC7773944</ArticleId><ArticleId IdType="pubmed">33392263</ArticleId></ArticleIdList></Reference><Reference><Citation>Schanin J, Gebremeskel S, Korver W, et al. A monoclonal antibody to Siglec&#x2010;8 suppresses non&#x2010;allergic airway inflammation and inhibits IgE&#x2010;independent mast cell activation. Mucosal Immunol. 2020;14:366&#x2013;376. 10.1038/s41385-020-00336-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41385-020-00336-9</ArticleId><ArticleId IdType="pmc">PMC7946634</ArticleId><ArticleId IdType="pubmed">32814824</ArticleId></ArticleIdList></Reference><Reference><Citation>Peter AE, Sandeep BV, Rao BG, Kalpana VL. Calming the storm: natural immunosuppressants as adjuvants to target the cytokine storm in COVID&#x2010;19. Front Pharmacol. 2020;11:583777. 10.3389/fphar.2020.583777</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2020.583777</ArticleId><ArticleId IdType="pmc">PMC7941276</ArticleId><ArticleId IdType="pubmed">33708109</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>